The burgeoning popularity of retatrutide, initially for metabolic conditions, is creating significant attention within the UK , prompting a notable shift in peptide trends. Access these compounds remains a complex landscape, with public healthcare system provision currently limited and private clinics offering therapy at a premium . Worries are bei